(Q26991810)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22520846%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Janus kinase deregulation in leukemia and lymphoma (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22520846%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22520846%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Edwin Chen

series ordinal

1

2 references

Crossref

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22520846%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Louis M Staudt

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22520846%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

1 reference

1 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22520846%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22520846%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

36

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22520846%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22520846%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

529-541

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22520846%20AND%20SRC:MED&resulttype=core&format=json

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

29 January 2020

cites work

1 reference

12 December 2020

Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia

1 reference

12 December 2020

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

1 reference

12 December 2020

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

12 December 2020

MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

1 reference

12 December 2020

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

12 December 2020

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

1 reference

12 December 2020

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

1 reference

12 December 2020

Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice

1 reference

12 December 2020

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

1 reference

12 December 2020

JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.

1 reference

12 December 2020

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia

1 reference

12 December 2020

Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.

1 reference

12 December 2020

IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line

1 reference

12 December 2020

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

1 reference

12 December 2020

Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB

1 reference

12 December 2020

Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases

1 reference

12 December 2020

Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome

1 reference

12 December 2020

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden

1 reference

12 December 2020

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling

1 reference

12 December 2020

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

1 reference

12 December 2020

Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells

1 reference

12 December 2020

Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin

1 reference

12 December 2020

Identification of somatic JAK1 mutations in patients with acute myeloid leukemia

1 reference

12 December 2020

Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells

1 reference

12 December 2020

Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia

1 reference

12 December 2020

Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.

1 reference

12 December 2020

BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas

1 reference

12 December 2020

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

1 reference

12 December 2020

Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis

1 reference

12 December 2020

Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia

1 reference

12 December 2020

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

1 reference

12 December 2020

Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia.

1 reference

12 December 2020

A progenitor cell origin of myeloid malignancies

1 reference

12 December 2020

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

1 reference

12 December 2020

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

1 reference

12 December 2020

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

1 reference

12 December 2020

Stat5 synergizes with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma

1 reference

12 December 2020

JAK signaling globally counteracts heterochromatic gene silencing

1 reference

12 December 2020

Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators

1 reference

12 December 2020

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

1 reference

12 December 2020

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

1 reference

12 December 2020

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

12 December 2020

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

1 reference

12 December 2020

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

1 reference

12 December 2020

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.

1 reference

12 December 2020

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

1 reference

12 December 2020

Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones

1 reference

12 December 2020

Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage.

1 reference

12 December 2020

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

1 reference

12 December 2020

Polycythemia vera is not initiated by JAK2V617F mutation.

1 reference

12 December 2020

Guideline for investigation and management of adults and children presenting with a thrombocytosis

1 reference

12 December 2020

Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.

1 reference

12 December 2020

JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

1 reference

12 December 2020

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

1 reference

12 December 2020

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

1 reference

12 December 2020

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

1 reference

12 December 2020

Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis.

1 reference

12 December 2020

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

1 reference

12 December 2020

Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells

1 reference

12 December 2020

Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders

1 reference

12 December 2020

Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.

1 reference

12 December 2020

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.

1 reference

12 December 2020

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia

1 reference

12 December 2020

Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.

1 reference

12 December 2020

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas

1 reference

12 December 2020

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

12 December 2020

CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP

1 reference

12 December 2020

Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation

1 reference

12 December 2020

Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia

1 reference

12 December 2020

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

1 reference

12 December 2020

Oncogenically active MYD88 mutations in human lymphoma

1 reference

12 December 2020

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

12 December 2020

Cooperative epigenetic modulation by cancer amplicon genes

1 reference

12 December 2020

STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma

1 reference

12 December 2020

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma

1 reference

12 December 2020

Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells

1 reference

12 December 2020

Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB.

1 reference

12 December 2020

Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7.

1 reference

12 December 2020

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling

1 reference

12 December 2020

Critical requirement for Stat5 in a mouse model of polycythemia vera

1 reference

12 December 2020

Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene.

1 reference

12 December 2020

Activating mutations in human acute megakaryoblastic leukemia.

1 reference

12 December 2020

Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells

1 reference

12 December 2020

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

12 December 2020

Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.

1 reference

12 December 2020

JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study

1 reference

12 December 2020

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

1 reference

12 December 2020

The role of Janus kinases in haemopoiesis and haematological malignancy

1 reference

12 December 2020

JAK mutations in high-risk childhood acute lymphoblastic leukemia

1 reference

12 December 2020

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity

1 reference

12 December 2020

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

1 reference

12 December 2020

Mouse models of myeloproliferative neoplasms: JAK of all grades

1 reference

12 December 2020

Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.

1 reference

12 December 2020

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

1 reference

12 December 2020

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

1 reference

12 December 2020

JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors

1 reference

12 December 2020

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

1 reference

12 December 2020

Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias

1 reference

12 December 2020

A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia

1 reference

12 December 2020

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

1 reference

12 December 2020

Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.

1 reference

12 December 2020

Activating alleles of JAK3 in acute megakaryoblastic leukemia

1 reference

12 December 2020

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells

1 reference

12 December 2020

Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system

1 reference

12 December 2020

Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers

1 reference

12 December 2020

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome

1 reference

12 December 2020

Mutation in TET2 in myeloid cancers

1 reference

12 December 2020

The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation

1 reference

12 December 2020

STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant

1 reference

12 December 2020

FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma

1 reference

12 December 2020

Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.

1 reference

12 December 2020

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

1 reference

12 December 2020

Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias

1 reference

12 December 2020

X-linked clonality testing: interpretation and limitations

1 reference

12 December 2020

Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2

1 reference

12 December 2020

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

12 December 2020

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

1 reference

12 December 2020

The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice

1 reference

12 December 2020